Autonomix Medical (AMIX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Sep, 2026Executive summary
Annual stockholder meeting scheduled for October 29, 2026, at 10:00 AM CST at 21 Waterway Avenue, Suite 300, The Woodlands, TX.
Shareholders can access proxy materials and vote online until October 28, 2026, 10:59 PM CST.
Record date for voting eligibility is September 8, 2026.
Voting matters and shareholder proposals
Election of six director nominees to serve until the 2027 annual meeting or until successors are elected.
Ratification of Forvis Mazars, LLP as independent registered public accounting firm for the year ending March 31, 2027.
Approval of an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1-for-2 and 1-for-25, at the Board's discretion, within one year of the meeting.
Approval of the amended and restated 2023 Equity Incentive Plan.
Board of directors and corporate governance
Six nominees for the Board: Walter V. Klemp, Lori Bisson, Jonathan P. Foster, David Robins, Christopher Capelli, and Sandra Kalter.
Latest events from Autonomix Medical
- Shareholders will vote on director elections, auditor ratification, a reverse split, and equity plan expansion.AMIX
Proxy filing - Board seeks approval for director elections, auditor, reverse split, and expanded equity plan.AMIX
Proxy filing - Registering 1,071,826 shares for resale via warrants, with proceeds for working capital if exercised.AMIX
Registration filing - Precision-guided nerve ablation technology shows strong clinical results and targets a $100B market.AMIX
Investor presentation - Net loss narrowed, cash runway shortens, and new capital raised via warrant inducement amid going concern risks.AMIX
Q1 2027 - Registering 857,462 shares for resale via warrants, with proceeds for working capital and high dilution risk.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with high risk and significant capital needs.AMIX
Registration filing - Medical device firm targets $200M shelf and $2.1M ATM amid high risk and going concern warning.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with no revenue and high ongoing losses.AMIX
Registration filing